Print
Email
Print Edition StoriesOne day after closing on a licensing deal for a drug development platform, Brighton’s Nano Terra Inc. has closed on a $2.3 million funding round, according to federal documents.
The filing with the U.S. Securities and Exchange Commission does not list by name the sole investor in the fundraise. Cited as related persons in the document are chairman and co-founder George Whitesides, and vice chairman and co-founder Carmichael Roberts of North Bridge Venture Partners. Also listed are CEO Myer Berlow and COO Eric Keller.
The funding follows just a few months after the company’s most recent fundraise, in which Nano Terra took in $17.2 million of a planned $23.6 million venture funding round. That news also came from a government document filing, and none of the six backers were identified. Nano Terra does not list its investors on the company website, but the New York investment firm Harris & Harris Group Inc. announced a $750,000 investment in Nano Terra in February.
Nano Terra is developing so-called “smart materials,” including ultra-thin electronic displays, fuel cells, sensors and solar power devices, based on technology developed by Harvard University professor and serial entrepreneur Whitesides.
On Monday, Nano Terra awarded an exclusive worldwide license to three disease-oriented product candidates and rights to its Pharmacomer drug discovery platform to New York City biotechnology firm Kadmon Pharmaceuticals LLC. NanoTerra bought the developer of the Pharmacomer platform, Surface Logix Inc. – also a Whitesides company and also based in Brighton – for an undisclosed amount.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
